Catch up on the latest imaging research presented at the recent American Society for Radiation Oncology (ASTRO) Annual Meeting.
|Articles|June 5, 1996
Resolution Pharmaceuticals inks deals
Radiopharmaceutical developer Resolution Pharmaceuti-cals of Mississauga,Ontario, has entered into two R&D collaborations with Canadianinstitutes to develop new imaging agents. Both deals have thesupport of Canadian research agencies. In the first
Advertisement
Radiopharmaceutical developer Resolution Pharmaceuti-cals of Mississauga,Ontario, has entered into two R&D collaborations with Canadianinstitutes to develop new imaging agents. Both deals have thesupport of Canadian research agencies.
In the first deal, Resolution and the Alberta Peptide Institutewill receive up to $200,000 from the National Research Council'sIndustrial Research Assistance Program to investigate new radiopharmaceuticalsto image bacterial and fungal infections.
In the second deal, Resolution and the Ontario Cancer Centerreceived a $50,000 grant from the Medical Research Council ofCanada to research compounds to be used in functional medicalimaging that could also be used to aid disease treatment suchas chemotherapy.
Resolution Pharmaceuticals is a joint venture between Canadianradioisotope producer Nordion International and Allelix Biopharmaceuticals.The company's peptide-based radiopharmaceutical for imaging inflammatorydisease completed phase I clinical testing earlier this year (SCAN1/17/96).
Advertisement
Related to this article
Tightness of the high-convexity sulci (THC) on brain MRI was associated with nearly threefold higher odds of cognitive decline over five to seven years of follow-up, according to a new prospective study involving over 2,100 community-dwelling senior citizens.
An AI model for prostate MRI offered an 89 percent AUC for prostate cancer detection in external validation testing, according to a newly published international multicenter study.
In the latest episode of her Breast Imaging in Focus series, Manisha Bahl, MD, MPH, FSBI, discusses new research comparing mammography-based AI models for breast cancer detection and short-term risk prediction.
In a recent episode of our Molecular Imaging in Focus series, Jack Andrews, MD, discussed pertinent findings from a recent intra-patient comparative study of PSMA PET agents in men with recurrent prostate cancer presented at the recent ASTRO conference.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Expert Radiology is a **radiologist-run teleradiology practice with 10 years of experience**, hiring teleradiologists earning **$500–$900/hr with per-dictation pay**. Work from anywhere with true flexibility, **no shifts, no call, and no weekends**.
Our case mix is **predominantly outpatient and noncontrast**, with approximately **75% MRI**, plus X-ray and CT.
We cover **malpractice with tail**, handle all medical licensing, and ship you a **$10K reading station with six vertical 4K monitors**.
Minimum commitment is an **average of 400 cases per month**.
**Book a call with Brandi Escapule, Principal, Physician Services.**
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What a Large Prostate MRI Study Reveals About AI and Unassisted Radiologist Assessment
2
MRI Study Links Tightness of High-Convexity Sulci to Higher Risk of Cognitive Decline in Older Adults
3
Breast Imaging in Focus: Can AI Models for Breast Cancer Detection and Risk Prediction Be Used Interchangeably?
4
Research Highlights from the ASTRO 2026 Annual Meeting
5